|
KMID : 1040620190250030234
|
|
Clinical and Molecular Hepatology
2019 Volume.25 No. 3 p.234 ~ p.244
|
|
|
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
|
|
Na Seong-Kyun
Song Byung-Cheol
|
|
|
Abstract
|
|
|
|
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5?4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC.
|
|
|
KEYWORD
|
|
|
Chronic hepatitis C, Sustained virologic response, Hepatocellular carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|